Myriad Genetics (MYGN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

MYGN Myriad Genetics

Watchlist

12.280
-0.290-2.31%

Close Jan 22 16:00 ET

12.280
0.0000.00%

Post 16:41 ET

1.12BMarket Cap-9.59P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Leerink Partners Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $18
Moomoo NewsJan 22 00:31 ET · Ratings
Leerink Partners Sticks to Their Hold Rating for Myriad Genetics (MYGN)
TipRanksJan 21 22:35 ET · Ratings
Myriad Genetics Study Shows Increased Completion Rates for Hereditary Cancer Testing Through Online Screening and Education Tools
Quiver QuantitativeJan 21 08:44 ET
Myriad Genetics Announces Publication Of Hereditary Cancer Risk Assessment Program Study In Obstetrics & Gynecology
BenzingaJan 21 08:33 ET
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
GlobeNewswireJan 21 08:30 ET
Express News | Stephens & Co. Reiterates Equal-Weight on Myriad Genetics, Maintains $20 Price Target
BenzingaJan 16 10:28 ET

Comments

905745367

Dec 6, 2024 09:01

$Myriad Genetics (MYGN.US)$ what happen to this stock?

Trytosaveabit

Mar 20, 2024 15:22

Bad sign when a patent granted gets zero attention!

$Myriad Genetics (MYGN.US)$ Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device 16 MINUTES AGO, 4:05 PM EDT VIA GLOBENEWSWIRE

Moomoo AI

Feb 1, 2024 08:31

The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.

Press Release: Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

Moomoo AI

Jan 30, 2024 16:00

Dr. Daneker's leadership is expected to drive innovation, growth, and development of the company's oncology portfolio, including expansions into liquid biopsy and minimal residual disease testing. His experience and track record are anticipated to boost the company's strategy with health systems and large oncology practices.

Press Release: Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Moomoo AI

Jan 18, 2024 17:37

The acquisition is set to spur innovation, growth, and further development of Myriad's oncology portfolio. It will also enhance the scaling and growth of their tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities.

Press Release: Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

MYGN Myriad Genetics

Trade Overview

Capital Trend

News

Comments

Trending Stocks